 PITTSBURGH, Sept. 28, 2021 GLOBE NEWSWIRE -- NeuBase Therapeutics, Inc. Nasdaq: NBSE NeuBase, a biotechnology platform company Drugging the GenomeTM to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a fireside chat at the virtual Chardan 5th Annual Genetic Medicines Conference being held October 4 - 5. 